Evan Leitner

Associate
Full contact info

Experience

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Partner, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington DC
Rebecca Ross
Special Counsel, Washington DC
Randy Sabett
Special Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington DC
Karen Tsai
Special Counsel, Washington DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Senior Paralegal, Boston

Related Practices & Industries

Merus – $172.5 Million Follow-on Offering

August 14, 2023

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Courtney Thorne
Partner, Boston
Div Gupta
Partner, New York
Evan Leitner
Associate, New York
David D. Kim
Associate, San Francisco
Charles York
Associate, New York
Kindall G. Jackson
Associate, Washington DC
Peter A. Haddad
Associate, San Diego

Related Practices & Industries

Aura Biosciences – $86.7 Million Follow-on Offering

November 30, 2022

Cooley advised the underwriters in Aura Biosciences’ $86.7 million follow-on offering. SVB Securities, Cowen and Evercore ISI acted as joint bookrunning managers for the offering. Aura is a clinical-stage biotechnology company that is leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Partners Rich Segal, Div Gupta and Daniel Goldberg led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Daniel I. Goldberg
Partner, New York
Evan Leitner
Associate, New York
Jesse Schulman
Associate, Washington DC
Kindall G. Jackson
Associate, Washington DC

Related Practices & Industries

Zentalis Pharmaceuticals – $200 Million Follow-On Offering

July 8, 2022

Cooley advised the underwriters in Zentalis Pharmaceuticals’ $200 million follow-on offering of 10,330,000 shares of common stock at an offering price of $19.38 per share. Zentalis is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting fundamental biological pathways of cancers. Partners Richard Segal and Div Gupta led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Evan Leitner
Associate, New York
Olivia Creser
Associate, New York

Related Practices & Industries

The Clorox Company – $1.1 Billion Unsecured Senior Notes Offering

May 13, 2022

Cooley advised the underwriters on The Clorox Company’s registered debt offering of $1.1 billion aggregate principal amount of investment grade unsecured senior notes. The offering consisted of $500 million of 4.400% senior notes due 2029 and $600 million of 4.600% senior notes due 2032. Partners Eric Blanchard and Richard Segal, and associates Evan Leitner, Matthew Kosior and Olivia Creser, led the Cooley team advising the underwriters.

Read more

Related contacts

Eric Blanchard
Partner, New York
Richard Segal
Partner, New York
Evan Leitner
Associate, New York
Olivia Creser
Associate, New York
Eileen Marshall
Partner, Washington DC
Francis Wheeler
Partner, Colorado

Related Practices & Industries

View more